CONTROLLED-RELEASE INDOMETHACIN AND SUSTAINED-RELEASE DICLOFENAC SODIUM IN THE TREATMENT OF RHEUMATOID-ARTHRITIS - A COMPARATIVE CONTROLLED CLINICAL-TRIAL

The efficacy and tolerability of a new, controlled-release indomethacin (7.5 mg) tablet was compared to that of a sustained-release diclofenac sodium (100 mg) tablet in 84 patients with rheumatoid arthritis. The study was designed as a double-blind, double-dummy crossover trial, patients being allocated at random to receive 1 active tablet and 1 placebo tablet of the alternative medication at night for 4 weeks before being crossed over to the alternative treatment for a further 4 weeks. Patient and clinical assessments on entry and at the end of each treatment period showed that pain scores for day and night, duration of morning stiffness, requirement for escape analgesia (paracetamol) and treatment preference were similar for both treatments. Both preparations also significantly improved the degree of joint tenderness compared to baseline (p<0.001), as measured by a modified Ritchie Articular Index. Incidence and severity of side-effects were comparable, with a significant improvement in degree of constipation reported for both treatments compared to baseline (p<0.05). The incidence and severity of headache was statistically significantly worse (p<0.05) for controlled-release indomethacin; however, there was no difference in any other parameter of tolerability. It was concluded that controlled-release indomethacin tablets (75 mg) given as a single night-time dose were as efficacious and well tolerated as sustained-release diclofenac sodium (100mg). © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.